>> I assume INCY executives and scientists evaluated Ponatinib and felt that it had enough potential to warrant handing Ariad $140 million, and more to come.
Well, if your point is $140m for Ariad EU operation and ponatinib EU rights without at least funding half of ponatinib ongoing clinical trials reflected ponatinib's true value, I don't disagree at all. That isn't worth that much to me if you use similar metrics to derive ponatinib remaining US value.
Market Data 
Markets 
AI
